Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 77.6%

Neg 0% Neu 77.6% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.